Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
AbstractPaclitaxel is one of the most widely used chemotherapeutic agents thanks to its effectiveness and broad spectrum of antitumor activity. However, it has a very poor aqueous solubility and a limited specificity. To solve these handicaps, a novel paclitaxel-trastuzumab targeted transport nanosystem has been developed and characterized in this work to specifically treat cancer cells that overexpress the human epidermal growth factor receptor-2 (HER2). Methods: Alginate and piperazine nanoparticles were synthetized and conjugated with paclitaxel:β-cyclodextrins complexes and trastuzumab. Conjugated nanoparticles (300 nm) were characterized and their internalization in HER2-overexpressing tumor cells was analyzed by immunofluorescence. Its specific antitumor activity was studied in vitro using human cell lines with different levels of HER2-expression. Results: In comparison with free paclitaxel:β-cyclodextrins complexes, the developed conjugated nanovehicle presented specificity for the treatment of HER2-overpressing cells, in which it was internalized by endocytosis. Conclusions: It seems that potentially avoiding the conventional adverse effects of paclitaxel treatment could be possible with the use of the proposed mixed nanovehicle, which improves its bioavailability and targets HER2-positive cancer cells. View Full-Text
- Supplementary File 1:
ZIP-Document (ZIP, 173 KB)
Share & Cite This Article
Nieto, C.; Centa, A.; Rodríguez-Rodríguez, J.A.; Pandiella, A.; Martín del Valle, E.M. Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors. Nanomaterials 2019, 9, 948.
Nieto C, Centa A, Rodríguez-Rodríguez JA, Pandiella A, Martín del Valle EM. Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors. Nanomaterials. 2019; 9(7):948.Chicago/Turabian Style
Nieto, Celia; Centa, Ariana; Rodríguez-Rodríguez, Jesús A.; Pandiella, Atanasio; Martín del Valle, Eva M. 2019. "Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors." Nanomaterials 9, no. 7: 948.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.